治疗耐药强迫症障碍中的抽象素增加:回顾性图表审查
Raíza Alves-Pereira, Mariana Fontes, Vivian Cordeiro
1Laboratório de Neuropsicofarmacologia, Serviço de Psiquiatria do Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia.
Clinical neuropharmacology
|January 9, 2024
概括
埃斯凯特胺在治疗耐药强迫症 (OCD) 方面表现有前途. 初步数据表明,胺可以减少一些患者的强迫症症状,这需要进一步的临床试验.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 谷氨酸在强迫症疾病 (OCD) 的病理生理学中起着关键作用.
- 胺和胺,N-甲基-D-阿斯巴甜酸抗体,是精神疾病的新兴治疗方法.
- 埃斯凯特胺在强迫症治疗中具有快速有效性和良好的耐受性.
研究的目的:
- 评估临床文档,以评估在治疗耐药性强迫症的治疗中埃斯基坦胺的疗效.
- 评估埃斯基坦胺作为强迫症治疗的正式指示的潜力.
主要方法:
- 回顾治疗耐药性强迫症患者接受单剂量埃斯基坦胺治疗的患者的回顾性图表审查.
- 评估强迫症和抑郁症状使用耶鲁-布朗强迫症-强迫症量表和蒙哥马利-阿斯伯格抑郁症评分量表.
- 使用描述性统计数据进行数据分析.
主要成果:
- 埃斯凯坦胺被给予了8名耐治疗的强迫症患者 (7名皮下,1名静脉注射).
- 服用后一周,25%的患者表现出治疗反应,50%的患者表现出部分反应.
- 在75%的受试者中存在并发性主要抑郁症,其中2人表现出抗抑郁药的反应.
结论:
- 初步发现表明,胺可以缓解一组患者的强迫症症状.
- 这些结果支持进一步的临床试验,用于治疗强迫症治疗中的埃斯基泰胺.
相关概念视频
Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
Obsessive-Compulsive Disorder
130
Obsessive-compulsive disorder (OCD) is a mental health condition characterized by recurrent obsessions, compulsions, or both, which consume significant time and interfere with daily functioning. Obsessions involve persistent, intrusive, and unwanted thoughts, images, or urges that evoke anxiety. Common examples include irrational fears of contamination or harm. Compulsions are repetitive behaviors or mental acts performed to reduce the anxiety caused by obsessions. For instance, individuals...
130
Antidepressant Drugs: MAOIs and Other Agents
237
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
237


